---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-035979"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T01:58:56.688738+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corcept Q3 revenue $123.6M (+22% YoY); raises FY 2023 guidance to $470-$480M

## Summary
- Revenue $123.6M (+22% YoY); net income $31.4M ($0.28 diluted EPS) vs $34.6M ($0.30) in Q3 2022.
- FY 2023 revenue guidance raised to $470-$480M from previous $455-$470M.
- Cash and investments $414.8M at Sept 30, up from $363.3M end of prior quarter.
- GRACE Phase 3 enrollment complete; NDA for relacorilant in Cushing's expected Q2 2024.
- Key 2024 trial readouts: GRADIENT (mid-2024), ROSELLA, DAZALS (year-end 2024), CATALYST prevalence (Q1 2024).

## SEC filing metadata
- accession: 0001628280-23-035979
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828023035979/0001628280-23-035979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828023035979/cort-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-035979
- JSON: https://secwatch.observer/filing/0001628280-23-035979.json
- Plain text: https://secwatch.observer/filing/0001628280-23-035979.txt

## Key facts
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported the quarter ended September 30, 2023 results: revenue $123.6 million, net income $31.4 million, EPS $0.28 (diluted). Guidance raised.
  - Period: the quarter ended September 30, 2023
  - Revenue: $123.6 million
  - Net income: $31.4 million
  - EPS: $0.28 (diluted)
  - Guidance: raised
  - Result: reported results
  source text: and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended September 30, 2023. Financial Results • Revenue of $123.6 million, a 22 percent increase from third quarter 2022 • Increase in 2023 revenue guidance to $470 – $480 million, from $455 – $470 million • Net income per common share of $0.28
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000162828023035979/0001628280-23-035979-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.